ArticleBlood cancer journal2025
A real-world experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myeloma.
Rachel Dileo et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
5 papers cite it
this papercites it